// App-Quantinova.ai

374 : Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST).

Researchers

Presenter

  • Johnathan K. Joffe

Principal Investigators

  • Laura Murphy

  • Gordon J. S. Rustin

  • Syed A Sohaib

  • Sarah Swift

  • Dipa Noor

  • Simona Wade

  • Elizabeth James

  • Rhian Gabe

  • Sally P Stenning

  • Marcia Hall

  • Anand Sharma

  • Jeremy Braybrooke

  • Jonathan Shamash

  • John Logue

  • Henry Hunter Taylor

  • Richard S. Kaplan

  • Robert A Huddart

Medical Centers

  • Bradford Royal Infirmary, West Yorkshire, United Kingdom

  • Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom

  • MRC Clinical Trials Unit, UCL, London, United Kingdom

  • Mount Vernon Hospital, Northwood, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • St James Institute of Oncology, Leeds, United Kingdom

  • Centre for Cancer Prevention, Queen Mary University of London, London, United Kingdom

  • Mount Vernon Cancer Centre, Middlesex, United Kingdom

  • Mount Vernon Hospital, Uxbridge, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Kent Oncology Centre, Maidstone, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Testicular cancer

  • Seminoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

  • Multicenteric

Phase

  • III

Study Id's

  • NCT00589537

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved